Login to Your Account

Wolwo Bio-Pharmaceutical rings in new year with first Chinese IPO since ban

By Cornelia Zou
Staff Writer

Wednesday, January 8, 2014

HONG KONG – In one of the first issues since Mainland China regulator lifted a ban on initial public offerings (IPOs), Zhejiang Wolwo Bio-Pharmaceutical Co. (SZ: 300357) plans to offer as many as 30 million shares for as much as ¥20.05 (US$3.30) per share.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription